| Issuer | % of Class | Filed | ||||
|---|---|---|---|---|---|---|
| Schedule 13D · 1 security · may seek to influence control | ||||||
|
Outlook Therapeutics, Inc.
13D/A
OTLK · 69012T305
|
16.4% |
8/14/2026
Event 8/12/2026
|
||||
| GMS Ventures & Investments | 16.4% | |||||
| Sukhtian Ghiath M. | 16.4% | |||||
Includes filings since 12/18/2024, when the SEC began requiring structured 13D and 13G data.